Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED COMPENSATION

v3.20.1
SHARE-BASED COMPENSATION
3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION
SHARE-BASED COMPENSATION
Restricted Stock Awards. The number of shares and weighted average grant price of restricted stock awards during the three months ended March 31, 2020 were as follows:
 
Number of Shares
 
Weighted Average Grant Price
Non-vested as of December 31, 2019
626,399

 
$
10.31

Restricted stock awards granted:
 
 
 
Non-employee directors
40,430

 
$
7.54

Employees
513,685

 
$
7.54

Vested
(282,263
)
 
$
10.44

Non-vested as of March 31, 2020
898,251

 
$
8.56


The total fair value of shares vested during the three months ended March 31, 2020 and 2019, determined using the closing price on the grant date, was $2.9 million and $2.5 million, respectively.
Stock Options. The Company did not grant any stock options during the three months ended March 31, 2020.
Employee Stock Purchase Plan (“ESPP”). In the first quarter of 2020, the Company, in connection with its entry into a definitive agreement to merge with Bristow, suspended the ESPP.
Total share-based compensation expense, which includes restricted stock and the ESPP, was $0.7 million and $0.8 million for the three months ended March 31, 2020 and 2019, respectively.